The tirzepatide discovery: from gut hormone research to Mounjaro

Step 1: scientists noticed that gut hormones did far more than digest food

The story starts not in a laboratory working on obesity, but in research into type 2 diabetes. From the 1980s onwards, physiologists studying the gut after meals noticed that two hormones, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), were released in large amounts the moment food arrived in the small intestine. These incretin hormones prompted the pancreas to release insulin in a glucose-dependent way, slowing stomach emptying and, importantly, reducing appetite signals in the brain.

Early drug developers focused almost entirely on GLP-1, because patients with type 2 diabetes showed blunted GLP-1 responses. GIP was largely set aside: some data suggested it lost effectiveness in people with established obesity or diabetes, leading researchers to question whether it was worth targeting at all. That cautious consensus would eventually be overturned. If you want a deeper account of the early laboratory work, the detailed history of tirzepatide's development traces that research thread further.

What the incretin field established, at least, was that these hormones were druggable. Semaglutide, a GLP-1 receptor agonist, proved that activating one of the two pathways produced clinically meaningful weight loss. Eli Lilly's scientists then asked a different question: what if both receptors were activated together?

Step 2: Eli Lilly's researchers built a single molecule that spoke to both receptors

Designing a molecule that binds two structurally distinct receptors without losing potency at either is a significant chemical engineering challenge. Eli Lilly's team created a synthetic peptide based on the GIP hormone's backbone, then engineered it to also bind the GLP-1 receptor with high affinity. The result was a single molecule, tirzepatide, that activates both pathways simultaneously.

A question our prescribers hear most weeks is whether tirzepatide is simply a stronger version of a GLP-1 medicine. It is not. The GIP component appears to work alongside GLP-1 in ways that amplify fat-burning signals in adipose tissue and may improve GLP-1 receptor sensitivity, which had been the stumbling block for GIP-only approaches. The precise interaction is still being studied, but the clinical results were striking enough to move the compound quickly through trials. The tirzepatide overview on this site covers the pharmacology in more accessible detail if you want to explore the mechanism further.

Tirzepatide is administered as a once-weekly subcutaneous injection via a pre-filled KwikPen. Treatment begins at 2.5mg, a dose whose job is to let the body adjust, with the prescriber titrating upward in roughly four-week steps through 5, 7.5, 10, 12.5 and 15mg. Understanding where each dose fits is part of the clinical assessment process; more on that is available on the licensed dose information page.

Step 3: the SURMOUNT programme turned laboratory science into licensed medicine

Before tirzepatide could be licensed for weight management, it had to pass through large phase 3 trials. SURMOUNT-1, the primary obesity trial, randomised 2,539 adults with obesity and no diabetes to tirzepatide or placebo over 72 weeks, published in the New England Journal of Medicine. Participants taking the 15mg dose achieved an average body-weight reduction of around 20–21%. That figure placed tirzepatide ahead of any previously licensed weight-management medicine in head-to-head comparisons.

NICE evaluated the full evidence base and published its appraisal, TA1026, in December 2024. It recommended tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related condition, with lower thresholds for some ethnic backgrounds under UK guidance. The MHRA granted the UK marketing authorisation for Mounjaro, the brand name, and it now carries a Black Triangle symbol indicating ongoing post-marketing safety monitoring.

For anyone thinking about what treatment might suit them, the weight-loss treatment overview sets out how tirzepatide compares with other licensed options. Cost is often part of that conversation too; the Mounjaro cost page explains how private pricing works and what a transparent fee actually covers.

Step 4: from licence to private prescription, and what that means in practice

A licence is the regulatory green light; it does not mean the medicine is available to everyone. On the NHS, access is phased according to strict eligibility criteria that are rolling out gradually through 2025 and 2026, as set out in NICE TA1026. Private clinics and online pharmacies registered with the GPhC can prescribe tirzepatide now, subject to a full clinical assessment. The Mounjaro and tirzepatide page addresses a common point of confusion about the name difference.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it is submitted. There are no algorithms making approval decisions. If you are curious about the clinical team behind that process, our clinical lead's profile gives some background. For anyone ready to find out whether they are clinically suitable, starting a free consultation is the first step.